Medical/Pharmaceuticals

Dizal Announces New Data from the Phase I/II Study of Golidocitnib in Refractory or Relapsed Peripheral T Cell Lymphoma Selected for Oral Presentation at 2022 EHA Annual Meeting

SHANGHAI, May 13, 2022 /PRNewswire/ -- Dizal (SSE: 688192) will present the data from an ongoing phase I/II study of golidocitnib, a selective JAK1 inhibitor, in refractory or relapsed peripheral T cell lymphoma (r/r PTCL) in oral session at the 27th European Hematology Association 2022 (EHA2022)...

2022-05-13 19:09 3412

Yiling Pharmaceutical: Lianhua Qingwen Approved in Nigeria

SHIJIAZHUANG, China, May 12, 2022 /PRNewswire/ -- Yiling Pharmaceutical disclosed Wednesday that it had received the medicine approval document for Lianhua Qingwen Capsules from the National Agency for Food and Drug Administration and Control (NAFDAC),Nigeria. The Product Category is Herbal and ...

2022-05-12 22:43 3113

Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-targeting CAR-T GC012F in RRMM and B-NHL and CD19/CD7 Dual-directed Allogeneic CAR-T GC502 in B-ALL at EHA2022 Congress

SAN DIEGO, Calif., SUZHOU and SHANGHAI, China , May 12, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of can...

2022-05-12 22:01 3802

BIORCHESTRA Participated in Formulation and Delivery

BOSTON, May 12, 2022 /PRNewswire/ -- BIORCHESTRA is a leading RNA therapeutics company that develops novel RNA-based therapeutics and drug delivery systems for neurodegenerative diseases.  BBB penetration in vivo confocal microscopy clip BIORCHES...

2022-05-12 21:00 2427

Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery

TAIPEI, May 12, 2022 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (TWO.6838 ) and AimMax Therapeutics, Inc. ( United States) report successful top-line results from CPN-301, the first of two pivotal Phase 3 clinical studies of APP13007, a novelophthalmic...

2022-05-12 20:00 2614

A novel universal antiviral drug introduced in Korea

- Hyundai Bioscience launches CP-COV03 Phase 2 clinical trials - "To be an innovative medicine like penicillin that led to victory in the bacterial war" - Significant changes to the 'vaccine-dependent' virus response system SEOUL, South Korea, May 12, 2022 /PRNewswire/ -- The birth of a universa...

2022-05-12 18:19 3986

Zhimeng Biopharma Announces Dosing of First Subject of Its Novel Antiepileptic Drug Candidate CB03 in First-in-Human Phase I Clinical Trial

SHANGHAI, May 11, 2022 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng"), announced dosing of the first participant in the US Phase I study in healthy subjects of its innovative small-molecule KCNQ2/3 selective opener (CB03), developed for the treatment of refractory epilepsy. CB03 is...

2022-05-12 08:00 2073

Asia's first molecular diagnostics company for women, INEX Innovate receives European CE-IVD Certification for its OvaCis(R) Rapid Test to detect cancer in ovarian cysts.

Revolutionary Ovarian Cancer Rapid Test Available Q4 2022 SINGAPORE, May 11, 2022 /PRNewswire/ -- Known as a pioneer in Asia's women's and fetal health industry,Singapore-based diagnostics developer, INEX Innovate has obtained a CE markfor its lead ovarian cancer product, the OvaCis® Rapid Test....

2022-05-11 22:00 3215

PharmAbcine to participate in Jefferies Global Healthcare Conference and BIO International Convention

DAEJEON, South Korea, May 11, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that Dr.Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to par...

2022-05-11 20:00 3245

Bridge Biotherapeutics to Announce Updated Data from its Phase 1 Study of BBT-176 in Advanced Non-Small Cell Lung Cancer in an Oral Presentation at IASLC 2022 World Conference on Lung Cancer

* Data analysis to explore demonstrated anti-tumor activity of BBT-176, a fourth generation EGFR TKI, in advanced non-small cell lung cancer SEONGNAM, South Korea , May 10 /PRNewswire/ -- Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on deve...

2022-05-10 21:00 2523

Nature Medicine Publishes Results from an Investigator-Initiated Trial of CARsgen's CT041 Claudin18.2 CAR T Cells in Gastrointestinal Cancers

SHANGHAI, May 10, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the phase I trial interim results of an investigator-initiated tri...

2022-05-10 20:50 2737

Harbour BioMed to Present the Latest Progress of Next-Generation Anti-CTLA-4 Antibody HBM4003 at 2022 ASCO Annual Meeting

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 10, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, today announced the Company w...

2022-05-10 16:54 3353

AffaMed Therapeutics Holds DEXTENZA Launch and Advisory Board Meeting in Macau

SHANGHAI, May 9, 2022 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products, held a DEXTENZA Launch and Advisory Board Meeting recently inMacau, f...

2022-05-10 09:00 2120

Formus Labs, a Pioneering Developer of Orthopedic Surgery Planning Technology, Hires Ex-Johnson & Johnson Executive, Polly Teevan, To Lead Global Commercial Strategy

Having managed a nearly $1 billion business in the world's largest orthopedic market, Teevan brings 20+ years of experience to help Formus improve patient lives AUCKLAND, New Zealand, May 10, 2022 /PRNewswire/ -- Formus Labs, creator of the world's first fully-automated 3D planner for joint repl...

2022-05-10 03:00 2341

iNtRON Biotechnology, Inc., Launches New Website

It aims to promote strategic collaborations in global while also highlights its many innovative advances and successful scientific ventures. BOSTON and SEOUL, South Korea, May 9, 2022 /PRNewswire/ -- The parent company of iNtODEWORLD, Inc., iNtRON Biotechnology, Inc., ("iNtRON" or "Company") is ...

2022-05-09 21:00 3004

AskGene Limited Announces Completion of USD 20 Million Series A Financing Led by Qiming Venture Partners and TF Capital

CAMARILLO, Calif. and NANJING, China, May 8, 2022 /PRNewswire/ -- AskGene Limited ("AskGene"), a clinical-stage biopharmaceutical company focusing on discovery and development of innovative biological drugs, today announced the completion ofUSD 20 million in Series A financing. The financing was ...

2022-05-09 11:37 6925

InxMed Raised $15 million in Series B+ Financing to Advance Innovative Therapies to Drug-resistant Cancers

NANJING, China, May 8, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors, today announced that it had completed $15 million in Series B+ Fin...

2022-05-09 08:04 2392

Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 5, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX:02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, is pleased to announce the appointment o...

2022-05-06 08:00 2773

AHRA and United Imaging launch a new program to develop exceptional leaders.

Announcing AHRA's Transformative Leaders of Choice Program HOUSTON, May 5, 2022 /PRNewswire/ -- AHRA, The Association for Medical Imaging Management, the professional organization representing all levels of management in hospital imaging departments, freestandin...

2022-05-05 22:15 2534

Daewoong Pharmaceutical announced first-quarter 2022 results

- Marked sales of KRW 272.2 billion and operating profit of KRW 26.8 billion - Reported record-high quarterly operating profit, thanks to highly profitable ETC drugs and export growth of Nabota - Expected to see increasing profitability and robust growth due to export expansion of Nabota and the...

2022-05-05 21:00 2739
1 ... 221222223224225226227 ... 261